FDA Approval
In an opinion piece published on MedPage Today, oncologist Vinay Prasad argues that the FDA's approval of lecanemab for Alzheimer's disease is premature and overlooks significant risks. He calls for more rigorous evidence before widespread use.
AI에 의해 보고됨 사실 확인됨
The U.S. Food and Drug Administration has approved Merck's Keytruda Qlex, a subcutaneous formulation of the cancer drug pembrolizumab, for use in adults across most solid tumor indications. Announced on September 19, 2025, this new injectable version offers a quicker administration time compared to the traditional intravenous method, potentially enhancing patient convenience and access to treatment. The approval highlights efforts to innovate drug delivery in oncology amid growing demands for efficient therapies.